Related Experiment Videos

Evidence for improvement in survival with antihypertensive combination treatment

Frank Ruschitzka1

  • 1Heart Failure/Transplantation Clinic, University Clinic Zurich, Switzerland. frank.ruschitzka@usz.ch

Journal of Hypertension
|December 14, 2011
PubMed

Insights

Effective hypertension management requires combination therapy. Combining an ACE inhibitor with a dihydropyridine calcium antagonist, like perindopril/amlodipine, shows strong evidence for improving cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Hypertension is a primary risk factor for cardiovascular diseases.
  • High morbidity and mortality rates linked to hypertension complications pose a significant public health challenge.
  • Current antihypertensive treatments often fail to achieve adequate blood pressure control, necessitating combination therapies.

Purpose of the Study:

  • To evaluate the efficacy of combination antihypertensive therapies.
  • To identify optimal drug combinations for improving cardiovascular outcomes and patient survival.
  • To highlight evidence supporting specific drug combinations in managing hypertension.

Main Methods:

  • Review of large-scale clinical outcome studies.
  • Analysis of combination therapies involving ACE inhibitors and dihydropyridine calcium antagonists.
  • Focus on evidence from trials such as ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

Main Results:

  • Combination therapy is frequently required to achieve target blood pressure levels in hypertensive patients.
  • Evidence suggests enhanced antihypertensive effects from combining multiple agents.
  • The combination of perindopril (an ACE inhibitor) and amlodipine (a dihydropyridine calcium antagonist) demonstrated significant clinical trial support.

Conclusions:

  • Combination antihypertensive therapy is crucial for effective blood pressure management.
  • The perindopril/amlodipine combination represents a well-supported therapeutic strategy.
  • Further research and clinical application of effective combination therapies are vital for improving cardiovascular health.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...